Because cell cycle-dependent protein kinases are thought to be a major underlying reason for CIN and drug resistance in cancer [13, 14, 34], we hypothesized that NEK2 might be involved in the mechanism by which ALDH1A1 promotes therapy resistance in myeloma. Here, NEK2 is linked to plasma cell myeloma.